- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 12:46 | EU advances plans to reduce reliance on drug imports | ||
| 12:46 | UAE approves AstraZeneca's Baxfendy for hypertension | ||
| 10:46 | Isomorphic Labs receives $2.1bn for AI drug development | ||
| Di | Makary resigns, with Diamantas named as acting FDA commissioner | ||
| Di | BMS and Hengrui forge $15.2bn alliance for early-stage drugs | ||
| Di | FDA weighs drug repurposing pathway for underserved diseases | ||
| Di | BridgeBio's Attruby challenges Pfizer's Vyndamax legacy in pivotal ATTR trial | ||
| Di | GSK and SBP Group team up to advance bepirovirsen launch in China | ||
| Di | Partner Therapeutics secures FDA approval for Bizengri | ||
| Mo | Cellular Intelligence licenses Novo's shelved Parkinson's cell therapy programme | ||
| Mo | FDA locks down post-approval pregnancy safety data framework | ||
| Mo | ACROBiosystems upgrades HEK293 licence solution for R&D compliance | ||
| Mo | BMS' Sotyktu secures EC approval for psoriatic arthritis | ||
| Fr | Gilead posts positive Q1 buoyed by HIV drug growth | ||
| Fr | Novo's CEO champions "record-breaking start" for Wegovy pill in US market | ||
| Fr | Construction begins on Novartis' RLT centre in Texas, US | ||
| Fr | Angelini Pharma to acquire Catalyst Pharmaceuticals for equity value of $4.1bn | ||
| Do | GSK spends $1bn on rights to SiranBio's metabolic oligonucleotide | ||
| Do | Eli Lilly pledges $4.5bn to bolster Indiana-based manufacturing | ||
| Do | Daiichi Sankyo and Waiv partner for ADC biomarkers | ||
| Do | Halozyme and Oruka sign agreement for Hypercon technology | ||
| 06.05. | Bayer looks to uphold Eylea legacy with $2.45bn Perfuse buyout | ||
| 06.05. | Citius raises $36.5m for Lymphir commercialisation | ||
| 06.05. | DDW 2026: key readouts from the conference | ||
| 06.05. | Arrowhead and Madrigal sign global licence for MASH RNAi therapy |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.